Halozyme Therapeutics (NASDAQ:HALO) Reaches New 12-Month High - Here's Why

Key Points

• Halozyme Therapeutics reached a new 52-week high, trading as high as $116.85 and last changing hands at $112.44. The stock’s market capitalization is approximately $12.76 billion.
• Recent quarterly results exceeded expectations, with EPS of $2.28 versus the $1.79 consensus estimate and revenue of $481 million, up 47.7% year over year. The company issued fiscal 2026 EPS guidance of $8.65–$9.00.
• Analyst sentiment remains positive, with nine Buy ratings and a consensus “Moderate Buy” rating, although the average price target of $91.20 is below the current share price. Insiders sold 91,474 shares worth about $9.4 million over the past 90 days.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) reached a new 52-week high on Thursday . The stock traded as high as $116.85 and last traded at $112.44, with a volume of 2702748 shares. The stock had previously closed at $115.13.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on HALO. Citigroup reaffirmed a "market outperform" rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Wall Street Zen raised shares of Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 8th. TD Cowen raised their price target on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Wells Fargo & Company lifted their price target on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the company an "equal weight" rating in a report on Friday, August 7th. Finally, Citizens Jmp upped their price objective on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a "market outperform" rating in a research report on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $91.20.

Halozyme Therapeutics Price Performance

The stock has a market cap of $12.76 billion, a P/E ratio of 33.56, a P/E/G ratio of 0.44 and a beta of 0.88. The company's 50 day moving average price is $98.92 and its 200-day moving average price is $79.32. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping the consensus estimate of $1.79 by $0.49. The firm had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The business's quarterly revenue was up 47.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current year.

Insider Activity

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the sale, the director directly owned 14,462 shares in the company, valued at approximately $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the transaction, the director owned 40,418 shares in the company, valued at $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 91,474 shares of company stock valued at $9,416,633. Company insiders own 2.50% of the company's stock.

Institutional Investors Weigh In On Halozyme Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of HALO. Measured Wealth Private Client Group LLC grew its holdings in shares of Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 124 shares during the last quarter. MidFirst Bank bought a new position in Halozyme Therapeutics in the 2nd quarter valued at about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Halozyme Therapeutics during the second quarter valued at approximately $28,000. Quantbot Technologies LP bought a new position in Halozyme Therapeutics during the 2nd quarter valued at $30,000. Finally, Harbour Investments Inc. lifted its stake in Halozyme Therapeutics by 152.5% during the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company's stock valued at $41,000 after acquiring an additional 372 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company's primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.